8-K
filed June 1, 2026, 4:22 PM ET
ticker ESPR
CIK 0001434868
other material
confidence high
sentiment neutral
materiality 0.50
Esperion shareholders approve 7M-share increase to 2022 equity incentive plan
Esperion Therapeutics, Inc.
- Stockholders approved Plan Amendment increasing 2022 Plan authorized shares by 7,000,000.
- J. Martin Carroll and Sheldon L. Koenig elected as Class I directors for terms ending 2029.
- Advisory vote on executive compensation approved with ~95.7M for, ~34.9M against.
- Ratification of Ernst & Young as auditor for FY2026 passed with ~167.1M for.
- All proposals passed at May 28, 2026 annual meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
Esperion Therapeutics, Inc. shareholders approved Amendment to 2022 Plan to increase authorized shares by 7,000,000 at the 2026-05-28 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-28
Exact text from the filing
For Against Abstain Broker Non-Votes 108,150,213 22,489,001 454,840 46,114,802
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
Esperion Therapeutics, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm at the 2026-05-28 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-28
Exact text from the filing
ective successors are duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”), (ii) to approve the non-binding advisory resolution on the compensation of the Company’s named executive officers (“Proposal 2”), (iii) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 3”), and (iv) to approve an amendment to the 2022 Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the 2022 Plan by 7,000,000 shares ("Proposal 4").
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
Esperion Therapeutics, Inc. shareholders approved Election of Class I directors at the 2026-05-28 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-28
Exact text from the filing
J. Martin Carroll 105,082,565 26,011,489 46,114,802 Sheldon L. Koenig 109,672,941 21,421,113 46,114,802
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
Esperion Therapeutics, Inc. shareholders approved Non-binding advisory resolution on the compensation of the Company’s named executive officers at the 2026-05-28 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-28
Exact text from the filing
's Board of Directors, each to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”), (ii) to approve the non-binding advisory resolution on the compensation of the Company’s named executive officers (“Proposal 2”), (iii) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 3”), and (iv) to approve an amendment to the 2022 Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the 2022 Plan by 7,000,000 shares ("Proposal 4").
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.